SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
Price : $35 *
At a glance
- Drugs Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms TR1US
- 09 Apr 2018 Status changed from active, no longer recruiting to completed.
- 22 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 17 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.